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For several millennia the human medicine is based on application of small bioactive 
molecules that are administered in the form of plant extracts or synthetic compounds. 
However, their use in modern medicine is not possible without a detailed understanding 
of their biochemical effects and identification of their molecular targets. Chemical 
proteomics based on the specific recognition between the bioactive molecule and the 
target molecule is currently the most widely used techniques for identification of 
molecular targets of small molecules. Compared to conventional biochemical methods 
(e.g. 2D electrophoresis), chemical proteomics represents particularly sensitive and very 
selective technique that enable successful identification of biomolecules from complex 
biological samples that are naturally presented in very small concentrations. Carbonyl-
reducing enzymes, which play an important role in physiology due to their involvement 
in metabolism of various endogenous (e.g. prostaglandins, steroid hormones) and 
xenobiotic (e.g. anthracyclines, oracin) substrates, also represent such low abundance 
biomolecules. Although the majority of today known carbonyl-reducing enzymes 
represent soluble proteins, there are many membrane-bound members in short chain 
dehydrogenases/reductases (SDR) superfamily. However, the knowledge on their role in 
metabolism of xenobiotics is quite poor. Based on the research on the reduction 
stereospecificity of anticancer drug oracin, there were predicted microsomal carbonyl-
reducing enzymes involved in the metabolism and inactivation. However, previous 
attempts to purify these enzyme failed. Although the obtained protein fractions exhibited 
metabolic activity towards oracin with desired stereospecificity, using non-selective 
purification techniques (ion-exchange chromatography, hydrophobic-interaction 
chromatography) was not possible to obtain desired enzymes in sufficient quantity and 
purity for their subsequent identification by MS.  
The aim of this project was to develop suitable affinity carrier capable to selectively 
purify carbonyl-reducing enzymes from complex biological samples. For this purpose 
several types of magnetic and non-magnetic beads were modified with anticancer drug 
oracin to form an affinity carrier. The carrier showing the best binding capacity was 
subsequently tested with a series of pure carbonyl-reducing enzymes and complex 
biological samples. The in-house developed affinity carrier was able to capture carbonyl-
reducing enzymes having affinity towards oracin in all cases. Thus, affinity carrier was 
implemented into purification protocol of human microsomal carbonyl-reducing 
enzymes. Obtained fractions exhibited metabolic activity towards oracin with desired 
stereospecificity of its reduction. Using mass spectrometry proteins DHRS1, RDH16 and 
17β-HSD6, with unknown affinity and metabolic activity towards oracin were successfully 
isolated and identified. Furthermore, enzyme 11β-HSD1 with already described affinity 
towards oracin was identified too. The affinity of enzymes DHRS1 and RDH16 towards 
oracin was subsequently demonstrated by using recombinant proteins. Although these 
recombinant proteins have not confirmed significant metabolic activity of this drug yet, 
their isolation and identification as its potential molecular target may indicate their role 
in biotransformation of other xenobiotics. 
